4.0 Article

The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice

Journal

ARTHRITIS AND RHEUMATISM
Volume 64, Issue 10, Pages 3334-3343

Publisher

WILEY-BLACKWELL
DOI: 10.1002/art.34556

Keywords

-

Categories

Funding

  1. Arthritis Research UK
  2. European Union (AutoCure Consortium)
  3. Amira Pharmaceuticals
  4. Gilead
  5. Takeda
  6. Boehringer Ingelheim
  7. Regulus Therapeutics
  8. Promedior
  9. Academy of Medical Sciences (AMS) [AMS-SGCL8-Smith] Funding Source: researchfish
  10. Medical Research Council [G9818340B] Funding Source: researchfish
  11. Versus Arthritis [19791] Funding Source: researchfish

Ask authors/readers for more resources

Objective CD248 (tumor endothelial marker 1/endosialin) is found on stromal cells and is highly expressed during malignancy and inflammation. Studies have shown a reduction in inflammatory arthritis in CD248-knockout (CD248-/-) mice. The aim of the present study was to investigate the functional effect of genetic deletion of CD248 on bone mass. Methods Western blotting, polymerase chain reaction, and immunofluorescence were used to investigate the expression of CD248 in humans and mice. Microcomputed tomography and the 3-point bending test were used to measure bone parameters and mechanical properties of the tibiae of 10-week-old wild-type (WT) or CD248-/- mice. Human and mouse primary osteoblasts were cultured in medium containing 10 mM beta-glycerophosphate and 50 mu g/ml ascorbic acid to induce mineralization, and then treated with platelet-derived growth factor BB (PDGF-BB). The mineral apposition rate in vivo was calculated by identifying newly formed bone via calcein labeling. Results Expression of CD248 was seen in human and mouse osteoblasts, but not osteoclasts. CD248-/- mouse tibiae had higher bone mass and superior mechanical properties (increased load required to cause fracture) compared to WT mice. Primary osteoblasts from CD248-/- mice induced increased mineralization in vitro and produced increased bone over 7 days in vivo. There was no decrease in bone mineralization and no increase in proliferation of osteoblasts in response to stimulation with PDGF-BB, which could be attributed to a defect in PDGF signal transduction in the CD248-/- mice. Conclusion There is an unmet clinical need to address rheumatoid arthritisassociated bone loss. Genetic deletion of CD248 in mice results in high bone mass due to increased osteoblast-mediated bone formation, suggesting that targeting CD248 in rheumatoid arthritis may have the effect of increasing bone mass in addition to the previously reported effect of reducing inflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available